CSPC OUYI PHARMACEUTICAL CO., LTD.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-03-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.e-cspc.com
Clinical Trials
23
Active:0
Completed:6
Trial Phases
4 Phases
Phase 1:7
Phase 2:7
Phase 3:8
+1 more phases
Drug Approvals
40
PHILIPPINES:38
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 3
8 (34.8%)Phase 1
7 (30.4%)Phase 2
7 (30.4%)Not Applicable
1 (4.3%)A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD
Not Applicable
Completed
- Conditions
- Invasive Mold Disease
- Interventions
- Drug: ABCD
- First Posted Date
- 2025-11-20
- Last Posted Date
- 2025-11-20
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT07239765
- Locations
- 🇨🇳
The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, China
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
Phase 3
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRDrug: Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XRDrug: Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XRDrug: Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XRDrug: Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 815
- Registration Number
- NCT07026968
- Locations
- 🇨🇳
No. 896, Zhongshan East Road, High-tech Industrial Development Zone, Shijiazhuang, Hebei, China
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
Phase 3
Recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Dextromethorphan and Bupropion Sustained-Release TabletsDrug: Placebo
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 388
- Registration Number
- NCT06958692
- Locations
- 🇨🇳
Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT06943950
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found